Omeros Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Omeros de 37% y 61.6% respectivamente, mientras que el BPA crecerá en un 41.5% al año.

Información clave

38.2%

Tasa de crecimiento de los beneficios

42.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.5%
Tasa de crecimiento de los ingresos	65.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	09 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?

Jun 05

Omeros posts preliminary results from COVID-19 patients treated with narsoplimab

May 28

CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab

May 04

What Kind Of Shareholders Own Omeros Corporation (NASDAQ:OMER)?

Mar 03

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:OMER - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	26	-134	N/A	N/A	2
12/31/2025	8	-156	N/A	N/A	2
12/31/2024	N/A	-176	N/A	N/A	2
6/30/2024	N/A	-200	-156	-155	N/A
3/31/2024	N/A	-179	-142	-142	N/A
12/31/2023	N/A	-175	74	75	N/A
9/30/2023	N/A	-182	84	84	N/A
6/30/2023	N/A	-185	90	90	N/A
3/31/2023	N/A	-182	103	103	N/A
12/31/2022	N/A	-182	-87	-86	N/A
9/30/2022	N/A	-183	-79	-79	N/A
6/30/2022	N/A	-173	-77	-77	N/A
3/31/2022	N/A	-181	-85	-85	N/A
12/31/2021	N/A	-192	-110	-110	N/A
9/30/2021	-63	-217	-110	-110	N/A
6/30/2021	-37	-211	-121	-121	N/A
3/31/2021	-24	-194	-131	-131	N/A
12/31/2020	N/A	-173	-100	-100	N/A
9/30/2020	97	-130	-105	-105	N/A
6/30/2020	100	-108	-78	-77	N/A
3/31/2020	114	-89	-56	-56	N/A
12/31/2019	N/A	-147	-60	-60	N/A
9/30/2019	100	-79	-62	-62	N/A
6/30/2019	75	-102	-92	-91	N/A
3/31/2019	50	-121	-106	-105	N/A
12/31/2018	30	-127	-104	-104	N/A
9/30/2018	22	-120	-84	-83	N/A
6/30/2018	39	-88	-58	-58	N/A
3/31/2018	54	-68	N/A	-35	N/A
12/31/2017	65	-53	N/A	-36	N/A
9/30/2017	64	-57	N/A	-43	N/A
6/30/2017	54	-63	N/A	-43	N/A
3/31/2017	46	-61	N/A	-48	N/A
12/31/2016	42	-67	N/A	-52	N/A
9/30/2016	35	-67	N/A	-57	N/A
6/30/2016	27	-73	N/A	-61	N/A
3/31/2016	21	-77	N/A	-64	N/A
12/31/2015	14	-75	N/A	-65	N/A
9/30/2015	7	-76	N/A	-64	N/A
6/30/2015	4	-74	N/A	-66	N/A
3/31/2015	1	-76	N/A	-64	N/A
12/31/2014	1	-74	N/A	-58	N/A
9/30/2014	1	-55	N/A	-43	N/A
6/30/2014	1	-50	N/A	-38	N/A
3/31/2014	1	-46	N/A	-32	N/A
12/31/2013	2	-40	N/A	-30	N/A
9/30/2013	3	-46	N/A	-42	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que OMER siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que OMER siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que OMER siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (61.6% al año) de OMER crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (61.6% al año) de OMER crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OMER se prevé que sea elevada dentro de 3 años.

Omeros Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 17% to US$5.83

Price target increased by 17% to US$7.00

No longer forecast to breakeven

Consensus revenue estimates increase by 113%

Price target increased to US$16.00

Consensus revenue estimates fall by 35%

Recent updates

Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024

Omeros: Troubled Company Working Its Way Out Of The Morass

Omeros Corporation Announces Executive Changes

Omeros Corporation announced that it expects to receive $92.1 million in funding

Omeros Corporation to Report Q1, 2024 Results on May 15, 2024

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation (NasdaqGM:OMER) announces an Equity Buyback for $50 million worth of its shares.

Omeros Corporation to Report Q4, 2023 Results on Apr 01, 2024

Omeros: Still Worth A Look Despite Narsoplimab Woes

New major risk - Share price stability

New major risk - Negative shareholders equity

Omeros Corporation to Report Q3, 2023 Results on Nov 09, 2023

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Price target decreased by 17% to US$5.83

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

New minor risk - Market cap size

Omeros Corporation to Report Q2, 2023 Results on Aug 09, 2023

Is Omeros (NASDAQ:OMER) A Risky Investment?

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Omeros Corporation to Report Q1, 2023 Results on May 09, 2023

Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt

Price target increased by 17% to US$7.00

No longer forecast to breakeven

Consensus revenue estimates increase by 113%

Insufficient new directors

Omeros Corporation to Report Q3, 2022 Results on Nov 09, 2022

Omeros: Taking It To The Max

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Omeros falls 11% after reporting clinical data for COVID-19 therapy

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros: Managing An Investment After A Winning Trade

Omeros Corporation to Report Q2, 2022 Results on Aug 09, 2022

Omeros granted FDA’s Orphan Drug designation for PNH candidate

Omeros: Follow The Bouncing Ball

Price target increased to US$16.00

Omeros: On Death's Door

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.57 loss in 1Q 2021)

Omeros Corporation to Report Q1, 2022 Results on May 10, 2022

Consensus revenue estimates fall by 35%

No longer forecast to breakeven

Omeros Corporation, Annual General Meeting, Jun 17, 2022

Omeros: The Weight Of The Wait, A Conundrum

Insufficient new directors

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Insufficient new directors

Omeros Corporation to Report Q4, 2021 Results on Mar 01, 2022

Omeros: Despite Its Promise, The CRL Is A Huge Obstacle

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

Price target decreased to US$15.00

Forecast to breakeven in 2024

Rayner Surgical Inc. completed the acquisition of OMIDRIA Franchise from Omeros Corporation (NasdaqGM:OMER).

Omeros: A New Year Beckons

Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates

Consensus revenue estimates increase to US$129.6m

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Price target decreased to US$22.50

Omeros: What's Left

Price target decreased to US$25.29

Omeros: The Prize Is Nigh (Again)

Independent Director exercised options to buy US$156k worth of stock.

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.61 loss in 2Q 2020)

Omeros: PDUFA Delay Presents An Opportunity

Co-Founder exercised options and sold US$801k worth of stock

Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentation at 2021 Annual Congress of the European Hematology Association